Ventripoint Diagnostics Ltd is a medical device company that is primarily engaged in the development and commercialization of cardiac diagnostic tools. It sells its products worldwide.
Shares Outstanding 138M
Shares Fully Diluted 145M
Recent Share Price CDN$.32 (US$.25)
52-Week Range CDN$.07-.68
Market Cap ca. CDN$52M (USD$42M)
Insider Ownership (FD) 6%
Public Float Ownership 94%
Cash 3 years
Symbol: TSX-V: VPT & OTC: VPTDF
Staying true to our story, Ventripoint Diagnostics Ltd. continues to be dedicated to developing quality, smart tools that help solve the immediate needs of our healthcare clinicians, and most importantly improves the clinical experience for our youngest to oldest patient.
KEY AND STRATEGIC GOALS
Read full report
Ventripoint has entered into a collaboration with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography of canines with the goal of expanding this technology to all animals.
VMS+ could eventually help treat our most loyal best friend.
EXPLORING NEW FRONTIERS FOR VMS+
LATEST PRESS RELEASES
April 20, 2021
Ventripoint Attends 23rd Annual Canadian Echo Weekend and Grants Stock Options
April 19, 2021
Ventripoint Extends Patent Portfolio with Foundational U.S. Provisional Patent Filing
of Heart Motion Tracking Technology
Ventripoint Collaborates with GE Healthcare to Bring More Functionality to its Cardiac Ultrasound Devices
April 27, 2021
Ventripoint Diagnostics Update and Q&A with George Adams, Alvira Macanovic and Dr. Mark Swaim
BioPub/Torrey Hills Capital Zoom Webinar
Topic: Ventripoint: Bigger and Better, with CEO Dr. George Adams